DR. SMILE MEDICAL GROUP Lays Groundwork for U.S. Rollout of CHIVA Therapy with HMO NPI Approval
New York, May 10, 2025 — DR. SMILE MEDICAL GROUP, INC., a global leader in minimally invasive vein care, has officially received its Health Maintenance Organization (HMO) designation under the U.S. National Provider Identifier (NPI) system. This regulatory milestone marks the organization’s formal integration into the U.S. healthcare ecosystem and enables the launch of its first American CHIVA Center in New York.
Originally developed in Europe, CHIVA (Conservative Hemodynamic Cure for Venous Insufficiency) is a clinical approach to treating varicose veins that preserves venous function while correcting reflux. Unlike conventional stripping or ablation methods, CHIVA minimizes tissue damage, reduces recovery time, and lowers recurrence rates. With more than two decades of international clinical data supporting its efficacy, CHIVA is now entering the U.S. through a fully compliant and structured pathway.
The newly granted HMO-type NPI allows DR. SMILE MEDICAL GROUP to operate as a Medical Service Organization (MSO), overseeing a multi-site CHIVA network while coordinating provider management, billing, and clinical documentation in accordance with U.S. regulations.
“The approval of our HMO NPI is not just an administrative step—it’s a clinical gateway,” said a company spokesperson. “It allows us to offer CHIVA as a regulated, accessible, and scalable solution for American patients suffering from chronic venous disease.”
The New York CHIVA Center will serve as the group’s flagship U.S. site, designed as both a clinical facility and a training hub for physicians interested in adopting CHIVA protocols. The center will integrate digital patient management systems, standardized diagnostic workflows, and outcomes tracking to ensure evidence-based care at every step.
Key Clinical and Operational Highlights:
Minimally Invasive Innovation: CHIVA offers functional vein preservation without thermal damage or general anesthesia.
Evidence-Based Protocols: Protocols are guided by decades of peer-reviewed data and global clinical practice.
Training & Dissemination: The New York CHIVA Center will also serve as a clinical teaching site for U.S. vascular specialists.
Compliance-Driven Model: HMO NPI enables seamless billing, referrals, and cross-state provider integration.
Following its New York debut, DR. SMILE MEDICAL GROUP plans to establish additional CHIVA Centers in Los Angeles and beyond, forming a North American hub that complements its existing footprint in Asia and Africa.
“Our mission is to advance vein care through science, compassion, and cross-border collaboration,” the spokesperson added. “CHIVA represents the future of venous disease treatment, and we are proud to bring it to the United States with full regulatory alignment.”